Succinobucol

Summary

Succinobucol (CHEMBL83626) is a phase-3 clinical-stage small molecule; indicated across 1 condition including diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 616.9 Da · C35H52O5S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL83626
Name	Succinobucol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	216325
Molecular formula	C35H52O5S2
Molecular weight	616.9
InChIKey	RKSMVPNZHBRNNS-UHFFFAOYSA-N

SMILES: CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)OC(=O)CCC(=O)O)C(C)(C)C

IUPAC name: 4-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]-4-oxobutanoic acid

Also known as: AGI-1067, Succinobucol, SUCCINOBUCOL, SuccinobucolÊ, SuccinobucolÂ

Patent coverage: 107 distinct patent families (244 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Vascular cell adhesion protein 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
VCAM1	5.22	IC50	6000	nM	CHEMBL_ACT_551287

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	2	MONDO:0005015	EFO:0000400

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00066898	PHASE3	UNKNOWN	ARISE - Aggressive Reduction of Inflammation Stops Events
NCT00525577	PHASE2/PHASE3	UNKNOWN	ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).